Bone marrow origin blood cancers and immune deficiencies are a complex set of medical conditions that need both pharmacologic and cellular therapies. My prior work in the laboratory has identified key therapeutic targets that can be advanced to clinical trials in the field of myeloid neoplasms. Working closely with other providers at Yale we offer both investigator initiated and industry sponsored clinical trials for patients with hematologic neoplasms needing transplantation or cellular immunotherapy (CAR-T, and other effector immune cells). My group also leads large international registry level research to identify barriers to curative intent cellular therapies and identify limitations and success with its application across different disease spectrum.
Targeted therapy; Transfusion Associated Immunomodulation, Immunotherapy, Cellular Therapy, Regenerative Medicine
Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Immunotherapy; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Hematopoietic Stem Cell Transplantation; Primary Myelofibrosis